Select Page

Develop and commercialize TXNIP [tix-nip] inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 Diabetes.

Develop and commercialize TXNIP [tix-nip] inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 Diabetes.

Diabetes is a major global and local health problem.

Diabetes currently affects 529 million people worldwide.

>38 million people in the U.S. have diabetes.

98 million adults in the U.S. have pre-diabetes.

425 Million People Worldwide
Insulin Pen Injector

There are no current oral medications for Type 1 diabetes.

To stay alive, individuals with Type 1 diabetes require multiple daily insulin injections and/or continuous insulin infusion.

None of the current oral medications address the problem of excessive glucagon levels associated with diabetes.

Approved treatments are also urgently needed for non-alcoholic fatty liver disease (NAFLD), which is often associated with diabetes.

No specific drug is available to inhibit TXNIP (thioredoxin-interacting protein), a newly identified therapeutic target.

There are no current oral medications for Type 1 diabetes.

To stay alive, individuals with Type 1 diabetes require multiple daily insulin injections and/or continuous insulin infusion.

None of the current medications address the problem of excessive glucagon levels associated with diabetes.

Approved treatments are also urgently needed for non-alcoholic fatty liver disease (NAFLD), which is often associated with diabetes.

No specific drug is available to inhibit TXNIP (thioredoxin-interacting protein), a newly identified therapeutic target.

Insulin Pen Injector

TIXiMED offers a solution – TIX100.

TIX100 is a novel, non-toxic small molecule that, given orally, protects against models of Type 1 and Type 2 diabetes as well as NAFLD.

TIXiMED is the exclusive license holder for the underlying patent (composition of matter and method of use) surrounding the TIX100 molecule.

Pill Container

How TIX100 Works

The TIX100 Advantage

Strong, peer-reviewed preclinical data (Thielen…Shalev, Cell Metabolism 2020)

TIX100 specifically targets TXNIP. This approach has successfully been translated to humans with T1D – see verapamil trials,(…2018, Xu…Shalev, Nature Communications 2020) and independently validated (CLVer trial, JAMA 2023)

TIX100 is more effective, more specific, and up to 100-times more potent in inhibiting TXNIP than verapamil 

Four sets of animal models and human islet studies indicate TIX100 efficacy

TIX100 caused NO hypoglycemia, NO fatty liver, NO hyperlipidemia, and NO weight gain
TIX100 has a favorable pharmacokinetic & safety profile
IND for TIX100 has been approved by the FDA, drug product has been manufactured, and TIX100 is ready to enter clinical trials

TIX100 is taken orally. By contrast, subjects with T1D need insulin given by multiple daily subcutaneous injections or an infusion to survive, and no oral medications are available.

TIX100 targets the underlying causes of the disease. It brings the elevated TXNIP levels back down into the normal range, protects beta cell insulin production, and inhibits the excessive secretion of glucagon typically seen in diabetes. (Glucagon counters the effects of insulin, making the blood sugar go even higher.) By doing so, TIX100 is also effective in the face of insulin deficiency.

Unlike current experimental glucagon receptor antagonist drugs, TIX100 lowers serum glucagon levels, reduces blood lipids, and protects against fatty liver, suggesting that it may also be effective in the context of NAFLD or non-alcoholic steatohepatitis (NASH).

Moving Forward

TIXiMED is targeting the fourth quarter of 2024 to begin Phase I human trials to demonstrate clinical safety.

Moving Forward

TIXiMED is targeting the fourth quarter of 2024 to begin Phase I human trials to demonstrate clinical safety.

Meet the team at TIXiMED >>

Meet the team at TIXiMED